Automation in Pharmacovigilance Data Processing – Do You Trust Artificial Intelligence?

May 16, 2017

Artificial intelligence (AI), machine learning, deep learning, natural language processing – in short, cognitive computing, is changing the pharmacovigilance world as we know it. While there’s a lot of talk about how AI will affect jobs, where it will have the most powerful impact is on the quality of work and the speed at which manual tasks can be accomplished.

This promises to be a game-changer for pharmacovigilance, decreasing the cost of case reporting and improving data quality to allow area experts to focus on where they truly add value, including signal detection in drug safety, pharmacovigilance analytics, and benefit-risk assessment.

Repetitive and routine manual tasks such as adverse event case reporting can be automated and tackled by AI in a very sophisticated and seamless way. These tasks, for which we have coined the term ‘pharmacodiligence‘ — in other words, the due diligence of collecting and processing data — are not strategic in the same way as activities such as benefit-risk assessment.

By building AI into the adverse event case processing and allowing pharmacovigilance resources to focus on strategic activities, life sciences companies will realize better outcomes. That’s because safety departments can work smarter and faster with reliable data at their fingertips.

That, in turn, means more time can be freed up for important activities such as benefit-risk assessment and more resources can be committed to higher human intelligence activities that are vital for the scientific interpretation of patient data.

Building Trust in Pharmacovigilance

One of the barriers to adopting AI and automation has been the ‘trust factor.’ Life sciences companies like the idea of AI, but they are concerned that automation won’t produce the same outcomes as manual case processing.

In reality, however, automation has come a very long way and is well entrenched in our lives in ways we may not realize. Think about flying. Auto landing systems were introduced to the aviation industry about 30 years ago and today all planes use automated landing systems. Let’s face it, if you can trust your own life with automation in aviation, trusting your pharmacovigilance data to advanced automation should be less of a leap.

Join ArisGlobal at the UK Pharmacovigilance Day in London on June 6, 2017, where Vivek Ahuja, Vice President, Global Pharmacovigilance will present on the topic of “Automation in Pharmacovigilance Data Processing – do you trust Artificial Intelligence?


About ArisGlobal

ArisGlobal is transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary Nava® cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® is a unified platform that boosts efficiency, ensures compliance, delivers actionable insights, and lowers total cost of ownership through multi-tenant SaaS architecture.

Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China. For more updates, follow ArisGlobal on LinkedIn and Twitter.

Additional Information

Connect with ArisGlobal on LinkedIn:
Follow @Aris_Global on Twitter:


Erika Thomas
+305-726-6601 |